Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Most Cited Paper
in Estrogen and related hormone effects
18 Months Post-Publication
Class of 2026
“Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
capivasertib · fulvestrant · hormone receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · CAPItello-291 · patient-reported outcomes · phase 3 trial · AKT inhibitor · endocrine therapy combination · quality of life assessment · Randomized double-blind placebo-controlled trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459